Published in Genes Dev on December 15, 2011
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Links between metabolism and cancer. Genes Dev (2012) 5.27
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell (2015) 2.60
Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer (2014) 2.09
In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol (2014) 1.72
Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev (2012) 1.71
Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep (2012) 1.46
Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol (2012) 1.21
KIT oncogene inhibition drives intratumoral macrophage M2 polarization. J Exp Med (2013) 1.18
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Anticancer flavonoids are mouse-selective STING agonists. ACS Chem Biol (2013) 1.12
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res (2014) 1.10
Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res (2014) 1.09
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08
B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07
A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene (2013) 1.06
B cells and their mediators as targets for therapy in solid tumors. Exp Cell Res (2013) 1.06
TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res (2015) 1.03
Defective TGF-β signaling in bone marrow-derived cells prevents hedgehog-induced skin tumors. Cancer Res (2013) 1.00
Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. Breast Cancer Res (2013) 0.98
Development and translational imaging of a TP53 porcine tumorigenesis model. J Clin Invest (2014) 0.98
Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 0.97
Video-rate resonant scanning multiphoton microscopy: An emerging technique for intravital imaging of the tumor microenvironment. Intravital (2012) 0.93
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat (2012) 0.93
Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther (2016) 0.93
Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol (2014) 0.92
Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. Genes Dev (2013) 0.91
Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res (2012) 0.90
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood (2014) 0.90
Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol (2015) 0.90
Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Sci Signal (2014) 0.88
Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87
Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol (2015) 0.87
Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. Oncoimmunology (2015) 0.87
Remodeling of tumor stroma and response to therapy. Cancers (Basel) (2012) 0.87
Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87
Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia (2012) 0.86
Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol (2015) 0.84
Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model. J Exp Clin Cancer Res (2014) 0.83
Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev (2015) 0.83
On the origin and destination of cancer stem cells: a conceptual evaluation. Am J Cancer Res (2013) 0.82
Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells. PLoS One (2013) 0.82
Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res (2015) 0.81
Mechanisms of Cancer Cell Dormancy-Another Hallmark of Cancer? Cancer Res (2015) 0.81
Are BiTEs the "missing link" in cancer therapy? Oncoimmunology (2015) 0.81
Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers. Cancers (Basel) (2014) 0.80
S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance. BMC Cancer (2015) 0.79
Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients (2016) 0.79
High-throughput approaches to discover novel immunomodulatory agents for cancer. Oncoimmunology (2012) 0.78
PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB. Cancer Res (2015) 0.78
Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma. Cell Mol Immunol (2015) 0.78
Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med (2015) 0.78
Human breast cancer biopsies induce eosinophil recruitment and enhance adjacent cancer cell proliferation. Breast Cancer Res Treat (2016) 0.77
Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration. BMC Cancer (2016) 0.77
Induction of premalignant host responses by cathepsin x/z-deficiency in Helicobacter pylori-infected mice. PLoS One (2013) 0.77
Neem leaf glycoprotein prophylaxis transduces immune dependent stop signal for tumor angiogenic switch within tumor microenvironment. PLoS One (2014) 0.77
New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci (2016) 0.77
Spatial and functional heterogeneities shape collective behavior of tumor-immune networks. PLoS Comput Biol (2015) 0.77
BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression. Oncoimmunology (2014) 0.76
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model. Cancer Gene Ther (2014) 0.75
Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective. Clin Exp Immunol (2015) 0.75
Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases. Oncotarget (2016) 0.75
Discovering cancer immunotherapy targets in vivo. Oncoimmunology (2014) 0.75
Current Studies of Immunotherapy on Glioblastoma. J Neurol Neurosurg (2014) 0.75
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8(+) T-cell Activation Against Tumors. Mol Ther (2015) 0.75
Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. Oncotarget (2016) 0.75
Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther (2015) 0.75
Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives. Oxid Med Cell Longev (2016) 0.75
Angiogenic inhibitors delivered by the type III secretion system of tumor-targeting Salmonella typhimurium safely shrink tumors in mice. AMB Express (2016) 0.75
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends Mol Med (2016) 0.75
Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther (2013) 0.75
Cerebral Gluconeogenesis and Diseases. Front Pharmacol (2017) 0.75
Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. Cancer Immunol Immunother (2016) 0.75
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenviron (2013) 0.75
Large molecular systems landscape uncovers T cell trapping in human skin cancer. Sci Rep (2016) 0.75
Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. Int J Mol Sci (2017) 0.75
Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc Natl Acad Sci U S A (2017) 0.75
Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Semin Cancer Biol (2017) 0.75
Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment. J Clin Invest (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Inflammation and cancer. Nature (2002) 53.78
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Immunity, inflammation, and cancer. Cell (2010) 28.27
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 10.83
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 5.16
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell (2011) 3.89
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev (2010) 3.56
Dendritic cell and macrophage heterogeneity in vivo. Immunity (2011) 3.41
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med (2011) 3.12
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94
A molecular perspective of CTLA-4 function. Annu Rev Immunol (2006) 2.71
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol (2006) 2.70
Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer (2003) 2.37
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 2.32
Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood (2009) 2.26
Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A (2010) 2.19
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Macrophages as mediators of tumor immunosurveillance. Trends Immunol (2010) 1.80
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Fine tuning the immune response through B7-H3 and B7-H4. Immunol Rev (2009) 1.72
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res (2010) 1.46
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood (2005) 1.38
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res (2005) 1.20
Human tumor antigens recognized by T-cells. Immunol Res (1997) 1.18
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev (2011) 1.15
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol (2006) 1.15
Randomized phase II trial of All-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.13
Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother (2008) 1.02
Dendritic cells: a critical player in cancer therapy? J Immunother (2008) 0.99
Biology and clinical applications of CD40 in cancer treatment. Semin Oncol (2010) 0.96
Modulation of macrophage function by gamma-irradiation. Acquisition of the primed cell intermediate stage of the macrophage tumoricidal activation pathway. J Immunol (1987) 0.91
Acute and persisting Th2-like immune response after fractionated colorectal gamma-irradiation. World J Gastroenterol (2008) 0.91
Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells. J Surg Oncol (1998) 0.82
Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin Lymphoma (2005) 0.81
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Tumor stroma and regulation of cancer development. Annu Rev Pathol (2006) 6.66
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 4.12
Cancer: an inflammatory link. Nature (2004) 3.88
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76
Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 3.18
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85
Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol (2009) 2.84
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev (2010) 2.41
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest (2008) 2.24
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol (2005) 2.06
Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol (2012) 2.05
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol (2006) 1.95
Polarized immune responses differentially regulate cancer development. Immunol Rev (2008) 1.95
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther (2013) 1.90
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
The contribution of bone marrow-derived cells to the tumor vasculature in neuroblastoma is matrix metalloproteinase-9 dependent. Cancer Res (2005) 1.84
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res (2011) 1.78
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol (2003) 1.63
B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc Natl Acad Sci U S A (2011) 1.58
MMP9 potentiates pulmonary metastasis formation. Cancer Cell (2002) 1.57
Inflammation, proteases and cancer. Eur J Cancer (2006) 1.52
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Res Treat (2015) 1.42
MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res (2011) 1.40
Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech (2010) 1.35
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn (2007) 1.35
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Antiemesis. J Natl Compr Canc Netw (2012) 1.28
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res (2012) 1.26
Cancer-related fatigue. J Natl Compr Canc Netw (2010) 1.26
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers. Clin Breast Cancer (2005) 1.25
Soluble mediators of inflammation during tumor development. Adv Cancer Res (2005) 1.24
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer (2013) 1.17
Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat (2012) 1.15
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res (2012) 1.12
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer (2013) 1.11
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol (2008) 1.11
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst (2013) 1.10
A selective activity-based probe for the papain family cysteine protease dipeptidyl peptidase I/cathepsin C. J Am Chem Soc (2006) 1.09
Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol (2013) 1.07
Early neoplastic progression is complement independent. Neoplasia (2005) 1.07
Inflaming gastrointestinal oncogenic programming. Cancer Cell (2008) 1.07
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov (2012) 1.06
Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer (2011) 1.04
Emerging treatments in chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol (2013) 1.03
Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol (2008) 1.02
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res (2013) 1.02
The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf (2010) 1.01
Implementing decision and communication aids to facilitate patient-centered care in breast cancer: a case study. Patient Educ Couns (2009) 1.01
Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil (2007) 1.01
TIMP-1 alters susceptibility to carcinogenesis. Cancer Res (2004) 1.01
Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw (2015) 1.00
Triple-negative breast cancer: role of antiangiogenic agents. Cancer J (2010) 0.99
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast Cancer Res Treat (2013) 0.99
Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Am J Physiol Lung Cell Mol Physiol (2004) 0.99
Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc (2006) 0.99
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol (2008) 0.99
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology . J Natl Compr Canc Netw (2014) 0.97
Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer (2009) 0.97
Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation (2002) 0.97
The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis (2012) 0.96
RECKing MMP function: implications for cancer development. Trends Cell Biol (2002) 0.96
Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning? J Clin Oncol (2012) 0.95
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Studying cancer-related fatigue: report of the NCCN scientific research committee. J Natl Compr Canc Netw (2010) 0.93
Delineating protease functions during cancer development. Methods Mol Biol (2009) 0.93
Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res (2007) 0.91